Latest news articles

Added 7 hours ago Drug news

EU approves Cabometyx for liver cancer.- Ipsen + Exelixis.

Exelixis announced that its partner Ipsen received approval from the European Commission (EC) for Cabometyx (cabozantinib) tablets as a monotherapy...

Added 7 hours ago Drug news

Updated data from registration enabling NAVIGATOR trial of avapritinib for patients with PDGFRalpha, D842V-driven GIST and in second-, third- and fourth-line for other GIST patients. Blueprint Medicines

Blueprint Medicines Corporation announced updated data for the registration-enabling NAVIGATOR clinical trial of avapritinib, a potent and highly selective KIT...

Added 1 day ago Drug news

TAPPAS phase III trial shows ApoStream effective in capturing tumour cells in angiosarcoma.- Precision for Medicine.

Precision for Medicine and TRACON Pharmaceuticals announced the publication of biomarker results from the TAPPAS phase III clinical trial that...

Search all news articles for Oncology
 

 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars in Oncology Knowledge Centre

Biosimilars in Oncology Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Load more

What's on the horizon?

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 1 year ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Marshall Pearce

Cancer immunotherapies

Posted 1 year ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Guidelines

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.

Added 4 months ago

Guidelines on Penile Cancer

The European Association of Urology (EAU) Guidelines on Penile Cancer provides up-to-date information on the diagnosis and management of penile squamous cell carcinoma (SCC).

Added 4 years ago

Guidelines on Primary Urethral Carcinoma

The European Association of Urology (EAU) Guidelines Group on Muscle-invasive and Metastatic Bladder Cancer has prepared these guidelines to deliver current evidence-based information on the diagnosis and treatment of patients with...

Added 3 years ago

Search all guidelines for Oncology
 

Journal articles

Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience.

The study aimed to describe real-life experience in advanced HCC treatment with SOR at a university hospital in Brazil and to estimate the number of patients with indication of second-line therapy.

Added 3 months ago

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.

The hepatocellular carcinoma (HCC) treatment landscape changed a decade ago, with sorafenib demonstrating survival benefit in the first-line setting and becoming the first systemic therapy to be approved for HCC.

Added 3 months ago

Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis.

This study aims to evaluate the effectiveness, safety and cost of abiraterone acetate (AA) in patients with mCRPC.

Added 3 months ago

Search all journal articles for Oncology
 

Clinical trials

Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma

The goal of this clinical research study is to compare the safety and effectiveness of cabozantinib and sunitinib when given to patients with metastatic (has spread) variant histology renal cell carcinoma (vhRCC), a type of kidney cancer.

Added 3 months ago

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer (EarLEE-2)

This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive...

Added 1 year ago

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150]

This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC)...

Added 3 months ago

Search all clinical trials for Oncology
 

Blog Posts

Advances in Precision Cancer Care

ESMO 2018 | Day 4 highlights

Posted 24 days ago

In our final report from ESMO 2018 we share insights from the Proffered paper session - Gastrointestinal tumours, colorectal, moderated by Dirk Arnold (Hamburg, DE) and Alfredo Falcone (Pisa, IT). Here, we cover survival data from the MODUL trial, comparing maintenance fluorouracil-bevacizumab and fluorouracil-bevacizumab plus atezolizumab in BRAF wild-type disease, and [in TRIBE2] consider the impact on PFS2 of an intensified treatment strategy versus a standard, sequential treatment strategy.

Advances in Precision Cancer Care

ESMO 2018 | Day 3 highlights

Posted 25 days ago

Sunday’s ESMO 2018 report comes from Presidential Symposium 2, moderated by Fortunato Ciardiello (Napoli, IT) and Josep Tabernero (Barcelona, ES). Here, we share key data and discussions from presentations on the STAMPEDE trial, looking at the role of prostate radiotherapy for patients with newly diagnosed metastatic prostate cancer and JAVELIN Renal 101, assessing avelumab plus axitinib as a first-line treatment option for patients with advanced renal cell carcinoma. 

Advances in Precision Cancer Care

ESMO 2018 | Day 2 highlights

Posted 26 days ago

Saturday’s ESMO 2018 report comes from Presidential Symposium 1, moderated by Andrés Cervantes (Valencia, ES) and Josep Tabernero (Barcelona, ES), discussing the scientific results and clinical implications of new data from the phase 3 IMpassion130, PALOMA-3 and SOLAR-1 trials. 

CME

Treatment Optimisation in Chronic Lymphocytic Leukaemia

Treatment Optimisation in Chronic Lymphocytic Leukaemia
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE

Managing the side effects of treatment for prostate cancer

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Personalisation of chronic lymphocytic leukaemia (CLL) care

Personalisation of chronic lymphocytic leukaemia (CLL) care
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE
Search all CME for Oncology